Julian D. Gillmore

Rowland Hill Street
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 382 publications

Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial.

Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial.

Journal: Journal of the American Heart Association

Published: August 31, 2026

Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy: A Meta-Analysis of Outcomes Trials.

Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy: A Meta-Analysis of Outcomes Trials.

Journal: JAMA

Published: August 30, 2026

From Static Staging to Dynamic Risk Prediction in Transthyretin Amyloid Cardiomyopathy.

From Static Staging to Dynamic Risk Prediction in Transthyretin Amyloid Cardiomyopathy.

Journal: JAMA cardiology

Published: August 28, 2026

Eplontersen for Transthyretin Amyloid Cardiomyopathy.

Eplontersen for Transthyretin Amyloid Cardiomyopathy.

Journal: The New England journal of medicine

Published: August 28, 2026

Electrocardiogram-Based Deep Learning to Prioritize Testing for Transthyretin Amyloid Cardiomyopathy.

Electrocardiogram-Based Deep Learning to Prioritize Testing for Transthyretin Amyloid Cardiomyopathy.

Journal: JAMA

Published: August 28, 2026

Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Secondary Analysis of the HELIOS-B Randomized Clinical Trial.

Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Secondary Analysis of the HELIOS-B Randomized Clinical Trial.

Journal: JAMA cardiology

Published: August 26, 2026

Left Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical Trial.

Left Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical Trial.

Journal: JAMA cardiology

Published: August 19, 2026

Vutrisiran Treatment and Changes in Cardiac Parameters and Amyloid Burden Assessed by Cardiovascular MRI.

Vutrisiran Treatment and Changes in Cardiac Parameters and Amyloid Burden Assessed by Cardiovascular MRI.

Journal: JAMA cardiology

Published: August 12, 2026

Effect of acoramidis on risk of death and heart problem-related hospitalizations in people with transthyretin amyloid cardiomyopathy: a plain language summary.

Effect of acoramidis on risk of death and heart problem-related hospitalizations in people with transthyretin amyloid cardiomyopathy: a plain language summary.

Journal: Future cardiology

Published: August 05, 2026

Plain language summary of how acoramidis affects the total number of heart problems over time in people with ATTR-CM: findings from the ATTRibute-CM study.

Plain language summary of how acoramidis affects the total number of heart problems over time in people with ATTR-CM: findings from the ATTRibute-CM study.

Journal: Future cardiology

Published: August 03, 2026

Effect of Acoramidis on Heart Failure-Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial.

Effect of Acoramidis on Heart Failure-Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial.

Journal: JAMA cardiology

Published: July 29, 2026

Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy.

Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy.

Journal: Circulation. Heart failure

Published: July 02, 2026

Showing 1-12 of 382

Last Updated: 09/26/2026